Peroxisome proliferator-activated receptors and hepatitis C virus

Therapeutic Advances in Gastroenterology

Volumn 4, Issue 6, 2011, Pages 419-431

  Eslam, M ^a   Khattab, M A ^a   Harrison, S A ^b  

^a MINIA UNIVERSITY   (Egypt)

^b BROOKE ARMY MEDICAL CENTER   (United States)

Author keywords

Hepatitis C; Insulin resistance; Liver fibrosis; Peroxisome proliferator activated receptors; Pioglitazone; Steatosis

Indexed keywords

ADIPONECTIN; ANTIVIRUS AGENT; BEZAFIBRATE; FATTY ACID; GLITAZONE DERIVATIVE; INSULIN; INTERFERON; PEGINTERFERON ALPHA2A; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; RIBAVIRIN; VIRUS PROTEIN;

ADD ON THERAPY; ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL THERAPY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG MECHANISM; FATTY LIVER; GLUCOSE METABOLISM; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; IMMUNOMODULATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; VIRUS PATHOGENESIS; VIRUS REPLICATION;

EID: 80054768851     PISSN: 1756283X     EISSN: 17562648     Source Type: Journal    
DOI: 10.1177/1756283X11405251     Document Type: Review

References (100)

1. Adinolfi L.E. Gambardella M. Andreana A. Tripodi M.F. Utili R. Ruggiero G. (2001) Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 33: 1358e64–1358e64.
2. Anderson S.P. Yoon L. Richard E.B. Dunn C.S. Cattley R.C. Corton J.C. (2002) Delayed liver regeneration in peroxisome proliferator-activated receptor-α-null mice. Hepatology 36: 544–554.
3. Allison M.E. Wreghitt T. Palmer C.R. Alexander G.J. (1994) Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol 21: 1135–1139.
4. Armoni M. Kritz N. Harel C. Bar-Yoseph F. Chen H. Quon M.J. et al (2003) Peroxisome proliferators activated receptor-gamma represses GLUT 4 promoter activity in primary adipocytes, and rosiglitazone alleviates this effect. J Biol Chem 278: 30614–30623.
5. Asselah T. Rubbia-Brandt L. Marcellin P. Negro F. (2006) Steatosis in chronic hepatitis C: why does it really matter? Gut 55: 123–130.
6. Bardot O. Aldridge T.C. Latruffe N. Green S. (1993) PPAR-RXR heterodimer activates a peroxisome proliferator response element upstream of the bifunctional enzyme gene. Biochem Biophys Res Commun 192: 37–45.
7. Berthiaume M. Sell H. Lalonde J. Gélinas Y. Tchernof A. Richard D. et al (2004) Actions of PPAR gamma agonism on adipose tissue remodeling, insulin sensitivity, and lipemia in absence of glucocorticoids. Am J Physiol Regul Integr Comp Physiol 287: R1116–R1123.
8. Browning J.D. Horton J.D. (2004) Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 114: 147e52–147e52.
9. Buettner R. Ottinger I. Scholmerich J. Bollheimer L.C. (2004) Preserved direct hepatic insulin action in rats with diet-induced hepatic steatosis. Am J Physiol Endocrinol Metab 286: E828–E833.
10. Caronia S. Taylor K. Pagliaro L. Carr C. Palazzo U. Petrik J. et al (1999) Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology 30: 1059–1063.
11. Castelein H. Gulick T. Declercq P.E. Mannaerts G.P. Moore D.D. Baes M.I. (1994) The peroxisome proliferator activated receptor regulates malic enzyme gene expression. J Biol Chem 269: 26754–26758.
12. Chang M.L. Yeh C.T. Chen J.C. Huang C.C. Lin S.M. Sheen I.S. et al. (2008) Altered expression patterns of lipid metabolism genes in an animal model of HCV core related, non obese, modest hepatic steatosis. BMC Genomics 9: 109–109.
13. Chehadeh W. Abdella N. Ben-Nakhi A. Al-Arouj M. Al-Nakib W. (2009) Risk factors for the development of diabetes mellitus in chronic hepatitis C virus genotype 4 infection. J Gastroenterol Hepatol 24: 42–48.
14. Cheng Y. Dharancy S. Malapel M. Desreumaux P. (2005) Hepatitis C virus infection down-regulates the expression of peroxisome proliferator-activated receptor alpha and carnitine palmitoyl acyl-CoA transferase 1A. World J Gastroenterol 11: 7591–7596.
15. Chu C.J. Lee S.D. Hung T.H. Lin H.C. Hwang S.J. Lee F.Y. et al. (2009) Insulin resistance is a major determinant of sustained virological response in genotype 1 chronic hepatitis C patients receiving peginterferon alpha-2b plus ribavirin. Aliment Pharmacol Ther 29: 46–54.
16. Conjeevaram H. Burant C.F. McKenna Harsh D. Kang H. Das A.K. et al. (2008) A randomized, double-blind, placebo-controlled study of PPAR gamma agonist pioglitazone given in combination with peginterferon and ribavirin in patients with genotype-1 chronic hepatitis C. Hepatology 48: 384A–384A.
17. Conjeevaram H.S. Kleiner D.E. Everhart J.E. Hoofnagle J.H. Zacks S. Afdhal N.H. et al. (2007) Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology 45: 80–87.
18. Dai C.Y. Huang J.F. Hsieh M.Y. Hou N.J. Lin Z.Y. Chen S.C. et al. (2009) Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. J Hepatol 50: 712–718.
19. de Gottardi A. Pazienza V. Pugnale P. Bruttin F. Rubbia-Brandt L. Juge-Aubry C.E. et al. (2006) Peroxisome proliferator-activated receptor-alpha and-gamma mRNA levels are reduced in chronic hepatitis C with steatosis and genotype 3 infection. Aliment Pharmacol Ther 23: 107–114.
20. den Boer M. Voshol P.J. Kuipers F. Havekes L.M. Romijn J.A. (2004) Hepatic steatosis: A mediator of the metabolic syndrome. Lessons from animal models. Arterioscler Thromb Vasc Biol 24: 644–649.
21. Desvergne B. Wahli W. (1999) Peroxisome proliferator-activated receptors: Nuclear control of metabolism. Endocr Rev 20: 649–688.
22. Dharancy S. Malapel M. Perlemuter G. Roskams T. Cheng Y. Dubuquoy L. et al. (2005) Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection. Gastroenterology 128: 334–342.
23. Eckel R.H. Grundy S.M. Zimmet P.Z. (2005) The metabolic syndrome. Lancet 365: 1415–1428.
24. Elgouhari H.M. Cesario K.B. Lopez R. Zein N. (2008) Pioglitazone improves early virologic kinetic response to PEG IFN/RBV combination therapy in hepatitis C genotype 1 naïve pts. Hepatology 48: 383A–383A.
25. Escher P. Wahli W. (2000) Peroxisome proliferator-activated receptors: Insight into multiple cellular functions. Mutat Res 448: 121–138.
26. Eslam, M., Khattab, M.A., Harrison, S.A. (2011) Insulin resistance and hepatitis C: an evolving story. Gut Jan 19.
27. Everett L. Galli A. Crabb D. (2000) The role of hepatic peroxisome proliferator-activated receptors (PPARs) in health and disease. Liver 20: 191–199.
28. Fajas L. Auboeuf D. Raspé E. Schoonjans K. Lefebvre A.M. Saladin R. et al. (1997) The organization, promoter analysis, and expression of the human PPARγ gene. J Biol Chem 272: 18779–18789.
29. Frohnert B.I. Hui T.Y. Bernlohr D.A. (1999) Identification of a functional peroxisome proliferator-responsive element in the murine fatty acid transport protein gene. J Biol Chem 274: 3970–3977.
30. Fukasawa M. Tanaka Y. Sato S. Ono Y. Nitahara-Kasahara Y. Suzuki T. et al. (2006) Enhancement of de novo fatty acid biosynthesis in hepatic cell line Huh7 expressing hepatitis C virus core protein. Biol Pharm Bull 29: 1958e61–1958e61.
31. Gearing K.L. Gottlicher M. Teboul M. Widmark E. Gustafsson J.A. (1993) Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor. Proc Natl Acad Sci U S A 90: 1440–1444.
32. Grimbert S. Valensi P. Levy-Marchal C. Perret G. Richardet J.P. Raffoux C. et al. (1996) High prevalence of diabetes mellitus in patients with chronic hepatitis C. A case–control study. Gastroenterol Clin Biol 20: 544–548.
33. Harsha D.W. Bray G.A. (2008) Weight loss and blood pressure control (Pro). Hypertension 51: 1420–1425. discussion 1425.
34. Hashimoto T. Cook W.S. Qi C. Yeldandi A.V. Reddy J.K. Rao M.S. (2000) Defect in peroxisome proliferators activated receptor α-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting. J Biol Chem 275: 28918–28928.
35. Hertz R. Bishara-Shieban J. Bar-Tana J. (1995) Mode of action of peroxisome proliferators as hypolipidemic drugs. Suppression of apolipoprotein C-III. J Biol Chem 270: 13470–13475.
36. Hess R. Staubli W. Riess W. (1965) Nature of the hepatomegalic effect produced by ethyl-chlorophenoxy-isobutyrate in the rat. Nature 208: 856–858.
37. Hickman I.J. Jonsson J.R. Prins J.B. Ash S. Purdie D.M. Clouston A.D. et al. (2004) Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 53: 413–419.
38. Hsu M.H. Savas U. Griffin K.J. Johnson E.F. (2001) Identification of peroxisome proliferators responsive human genes by elevated expression of the peroxisome proliferators activated receptor α in HepG2 cells. J Biol Chem 276: 27950–27958.
39. Hui J.M. Sud A. Farrell G.C. Bandara P. Byth K. Kench J.G. et al. (2003) Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology 125: 1695–1704.
40. Jay M.A. Ren J. (2007) Peroxisome proliferator-activated receptor (PPAR) in metabolic syndrome and type 2 diabetes mellitus. Curr Diabetes Rev 3: 33–39.
41. Kawaguchi T. Ide T. Taniguchi E. Hirano E. Itou M. Sumie S. et al. (2007) Clearance of HCV improves insulin resistance, betacell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol 102: 570–576.
42. Kersten S. Seydoux J. Peters J.M. Gonzalez F.J. Desvergne B. Wahli W. (1999) Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J Clin Invest 103: 1489–1498.
43. Khattab M. Emad M. Abdelaleem A. Eslam M. Atef R. Shaker Y. et al. (2010) Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance. Liver Int 30: 447–454.
44. Khattab M. Eslam M. Sharwae M.A. Shatat M. Ali A. Hamdy L. (2010) Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients. Am J Gastroenterol 105: 1970–1977.
45. Koike K. (2009) Steatosis, liver injury, and hepatocarcinogenesis in hepatitis C viral infection. J Gastroenterol 44(Suppl. 19)82–88.
46. Kotronen A. Westerbacka J. Bergholm R. Westerbacka J. Cornér A. Bergholm R. et al. (2007) Liver fat in the metabolic syndrome. J Clin Endocrinol Metab 92: 3490–3497.
47. Latruffe N. Cherkaoui Malki M. Nicolas-Frances V. Clemencet M.C. Jannin B. Berlot J.P. (2000) Regulation of the peroxisomal β-oxidation-dependent pathway by peroxisome proliferator-activated receptor α and kinases. Biochem Pharmacol 60: 1027–1032.
48. Le Brasseur N.K. Kelly M. Tsao T.S. Tsu-Shuen Tsao S.R. Asish K. et al. (2006) Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues. Am J Physiol Endocrinol Metab 291: E175–E181.
49. Lee S.S. Pineau T. Drago J. Lee E.J. Owens J.W. Kroetz D.L. et al. (1995) Targeted disruption of the alpha isoform of the peroxisome proliferator activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol 15: 3012–3022.
50. Lefebvre P. Chinetti G. Fruchart J.C. Staels B. (2006) Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest 116: 571–580.
51. Lerat H. Kammoun H.L. Hainault I. Mérour E. Higgs M.R. Callens C. et al. (2009) Hepatitis C virus (HCV) proteins induce lipogenesis and defective triglyceride secretion in transgenic mice. J Biol Chem 284: 33466e74–33466e74.
52. Mandard S. Müller M. Kersten S. (2004) Peroxisome proliferator-activated receptor a target genes. Cell Mol Life Sci 61: 393–416.
53. Mason A.L. Lau J.Y. Hoang N. Qian K. Alexander G.J. Xu L. et al. (1999) Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 29: 328–333.
54. Milner K.L. van der Poorten D. Trenell M. Jenkins A.B. Xu A. Smythe G. et al. (2010) Chronic hepatitis C is associated with peripheral rather than hepatic insulin resistance. Gastroenterology 138: 932–941. e1–e3.
55. Mirandola S. Realdon S. Iqbal J. Gerotto M. Dal Pero F. Bortoletto G. et al. (2006) Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis. Gastroenterology 130: 1661–1669.
56. Mizuta T. Kawaguchi Y. Eguchi Y. Takahashi H. Ario K. Akiyama T. et al. (2010) Whole-body insulin sensitivity index is a highly specific predictive marker for virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients with genotype 1b and high viral load. Dig Dis Sci 55: 183–189.
57. Monetti M. Levin M.C. Watt M.J. Sajan M.P. Marmor S. Hubbard B.K. et al. (2007) Dissociation of hepatic steatosis and insulin resistance in mice overexpressing DGAT in the liver. Cell Metab 6: 69–78.
58. Moriya K. Todoroki T. Tsutsumi T. Fujie H. Shintani Y. Miyoshi H. et al. (2001) Increase in the concentration of carbon-18 monounsaturated fatty acids in the liver with hepatitis C: Analysis in transgenic mice and humans. Biophys Biochem Res Commun 281: 1207–1212.
59. Moucari R. Asselah T. Cazals-Hatem D. Voitot H. Boyer N. Ripault M.P. et al. (2008) Insulin resistance in chronic hepatitis C: Association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 134: 416–423.
60. Nagasawa T. Inada Y. Nakano S. Tamura T. Takahashi T. Maruyama K. et al. (2006) Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPAR delta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. Eur J Pharmacol 536: 182–191.
61. Nagashima K. Lopez C. Donovan D. Ngai C. Fontanez N. Bensadoun A. et al. (2005) Effects of the PPAR gamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J Clin Invest 115: 1323–1332.
62. Nakamura M.T. Cheon Y. Li Y. Nara T.Y. (2004) Mechanisms of regulation of gene expression by fatty acids. Lipids 39: 1077–1083.
63. Negro F. (2009) Correction of insulin resistance in chronic hepatitis C patients not responding to the standard of care: More questions than answers. J Hepatol 50: 1271–1272.
64. Negro F. Sanyal A.J. (2009) Hepatitis C virus, steatosis and lipid abnormalities: Clinical and pathogenic data. Liver Int 29(Suppl. 2)26–37.
65. Neschen S. Morino K. Rossbacher J.C. Pongratz R.L. Cline G.W. Sono S. et al. (2006) Fish oil regulates adiponectin secretion by a peroxisome proliferator-activated receptorgamma-dependent mechanism in mice. Diabetes 55: 924–928.
66. Nuclear Receptors Nomenclature Committee (1999) A unified nomenclature system for the nuclear receptor superfamily. Cell 97: 161–163.
67. Oem J.K. Jackel-Cram C. Li Y.P. Zhou Y. Zhong J. Shimano H. et al. (2008) Activation of sterol regulatory element-binding protein 1c and fatty acid synthase transcription by hepatitis C virus non-structural protein 2. J Gen Virol 89: 1225e30–1225e30.
68. Overbeck K. Genné D. Golay A. Negro F. (2008) Pioglitazone in chronic hepatitis C not responding to pegylated interferon alpha and ribavirin. J Hepatol 49: 295–298.
69. Pajvani U.B. Hawkins M. Combs T.P. Rajala M.W. Doebber T. Berger J.P. et al. (2004) Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 279: 12152–12162.
70. Park C.Y. Jun H.J. Wakita T. Cheong J.H. Hwang S.B. (2009) Hepatitis C virus nonstructural 4B protein modulates sterol regulatory element-binding protein signaling via the AKT pathway. J Biol Chem 284: 9237e46–9237e46.
71. Patsouris D. Mandard S. Voshol P.J. Escher P. Tan N.S. Havekes L.M. et al. (2004) PPAR alpha governs glycerol metabolism. J Clin Invest 114: 94–103.
72. Pazienza V. Clément S. Pugnale P. Conzelman S. Foti M. Mangia A. et al. (2007) The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology 45: 1164–1171.
73. Pekow J.R. Bhan A.K. Zheng H. Chung R.T. (2007) Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis. Cancer 109: 2490–2496.
74. Perlemuter G. Sabile A. Letteron P. Vona G. Topilco A. Chrétien Y. et al. (2002) Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J 16: 185–194.
75. Petersen K.F. Dufour S. Savage D.B. Bilz S. Solomon G. Yonemitsu S. et al. (2007) The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc Natl Acad Sci U S A 104: 12587–12594.
76. Poustchi H. Negro F. Hui J. Cua I.H. Brandt L.R. Kench J.G. et al. (2008) Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol 48: 28–34.
77. Poynard T. Ratziu V. McHutchison J. Manns M. Goodman Z. Zeuzem S. et al. (2003) Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 38: 75e85–75e85.
78. Romero-Gómez M. Fernández-Rodríguez C.M. Andrade R.J. Diago M. Alonso S. Planas R. et al. (2008) Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol 48: 721–727.
79. Rubbia-Brandt L. Giostra E. Mentha G. Quadri R. Negro F. (2001) Expression of liver steatosis in hepatitis C virus infection and pattern of response to alpha-interferon. J Hepatol 35: 307–307.
80. Rubbia-Brandt L. Quadri R. Abid K. Giostra E. Malé P.J. Mentha G. et al. (2000) Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 33: 106–115.
81. Ryysy L. Häkkinen A.M. Goto T. Vehkavaara S. Westerbacka J. Halavaara J. et al. (2000) Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 49: 749–758.
82. Sakamoto J. Kimura H. Moriyama S. Odaka H. Momose Y. Sugiyama Y. et al. (2000) Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun 278: 704–711.
83. Savage D.B. Tan G.D. Acerini C.L. Jebb S.A. Agostini M. Gurnell M. et al. (2003) Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. Diabetes 52: 910–917.
84. Schoonjans K. Martin G. Staels B. Auwerx J. (1997) Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr Opin Lipidol 8: 159–166.
85. Schoonjans K. Peinado-Onsurbe J. Lefebvre A.M. Heyman R.A. Briggs M. Deeb S. et al. (1996) PPARα and PPARγ activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J 15: 5336–5348.
86. Seeff L.B. (2002) Natural history of chronic hepatitis C. Hepatology 36: S35–S46.
87. Sheikh M.Y. Choi J. Qadri I. Friedman J.E. Sanyal A.J. (2008) Hepatitis C virus infection: Molecular pathways to metabolic syndrome. Hepatology 47: 2127–2133.
88. Staels B. Vu-Dac N. Kosykh V.A. Saladin R. Fruchart J.C. Dallongeville J. et al. (1995) Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J Clin Invest 95: 705–712.
89. Su A.I. Pezacki J.P. Wodicka L. Brideau A.D. Supekova L. Thimme R. et al. (2002) Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci U S A 99: 15669–15674.
90. Svoboda D.J. Azarnoff D.L. (1966) Response of hepatic microbodies to a hypolipidemic agent, ethyl chlorophenoxyisobutyrate (CPIB). J Cell Biol 30: 442–450.
91. Tanaka N. Moriyam K. Kiyosawa K. Koike K. Gonzalez F.J. Aoyama T. (2008) PPAR alpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice. J Clin Invest 118: 683–694.
92. Tenenbaum H. Behar S. Boyko V. Adler Y. Fisman E.Z. Tanne D. et al. (2007) Long-term effect of bezafibrate on pancreatic beta-cell function and insulin resistance in patients with diabetes. Atherosclerosis 194: 265–271.
93. Thomopoulos K.C. Arvaniti V. Tsamantas A.C. Dimitropoulou D. Gogos C.A. Siagris D. et al. (2006) Prevalence of liver steatosis in patients with chronic hepatitis B: A study of associated factors and of relationship with fibrosis. Eur J Gastroenterol Hepatol 18: 233–237.
94. Uchimura K. Nakamuta M. Enjoji M. Irie T. Sugimoto R. Muta T. et al. (2001) Activation of retinoic X receptor and peroxisome proliferator-activated receptor-gamma inhibits nitric oxide and tumor necrosis factor-alpha production in rat Kupffer cells. Hepatology 33: 91–99.
95. Vanni E. Abate M.L. Gentilcore E. Hickman I. Gambino R. Cassader M. et al. (2009) Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C. Hepatology 50: 697e706–697e706.
96. Vierling J.M. Prbhaker A. Han J. Harrison S.A. et al. (2010) Virologic and metabolic responses in chronic hepatitis C (CHC) patients with insulin resistance (IR) treated with pioglitazone and peginterferon alpha-2 A plus ribavirin. Final results of week 12 early virologic response. Hepatology 52: 707A–707A.
97. Waris G. Felmlee D.J. Negro F. Siddiqui A. (2007) Hepatitis C virus induces the proteolytic cleavage of sterol regulatory element binding proteins (SREBPs) and stimulates the phosphorylation of SREBPs via oxidative stress. J Virol 81: 8122–8130.
98. World Health Organization (2000) Hepatitis C. Fact sheet number 164, revised October 2000. Available at: www.who.int/mediacentre/factssheets/fs164len [accessed 6 March 2009].
99. Yamauchi T. Kamon J. Ito Y. Tsuchida A. Yokomizo T. Kita S. et al. (2003) Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423: 762–769.
100. Yu Y.H. Ginsberg H.N. (2005) Adipocyte signaling and lipid homeostasis: Sequelae of insulin-resistant adipose tissue. Circ Res 2005 96: 1042–1052.